Early phase clinical trials

Early phase studies are often designed and implemented without substantive statistical input. The 3+3 maximum tolerated dose finding design being a classic example. This group aims to improve statistical aspects of early phase studies by bridging the gap between clinical trialists using traditional designs and modern statistical methodologists with many improvements to offer.

We are interested in reaching a consensus within the statistical community of which modern methods should be regarded as standard, and communicating these methods to a wider audience through training and education to increase their use in real-life trials.

Collaborative research enables us to consolidate our knowledge and share expertise. Our research section seeks to undertake collaborative working to promote high quality research by tackling discipline specific issues.

If you would like to be part of a research section or wish to find out more please email the NIHR Statistics Group.


Section leaders

Group Co-leader, Early Phase Clinical Trials

The Institute of Cancer Research

Group Co-leader, Early Phase Clinical Trials

Cambridge Clinical Trials Unit

Section committee members

The Institute of Cancer Research

University of Bath

University of Cambridge

Imperial College London

Early phase clinical trials Publications

Embracing model-based designs for dose-finding trials

British Journal of Cancer advance online publication 29 June 2017
Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose finding, such as the continual reassessment method

Find out more

Join the NIHR Statistics Group - Subscribe for the latest news, updates and event information.